Tag: Amgen

Amgen announced investment of $66 million in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.

Amgen announced that AMGEVITA, a biosimilar to adalimumab, to launch in markets across Europe. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).

The new plant is the first-of-its-kind in the USA and will use Amgen's proven next-generation biomanufacturing capabilities.

The increase experienced in the domestic industry with the incentives issued by the government in a program with the pharmaceutical industry among primary strategic products, drew the attention of top pharma players to Turkey.

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorisation of ABP 980, a biosimilar to Herceptin®.

Amgen and Pharmstandard announced the signing of an agreement on technology transfer, manufacturing and commercialization of blinatumomab in the Russian market